icon
icon
icon
icon
Upgrade
icon

Cryoport Unveils IntegriCell™ and Houston Facility: Revolutionizing Cell and Gene Therapy Supply Chains

AInvestMonday, Oct 7, 2024 8:35 am ET
1min read
Cryoport, a leading provider of temperature-controlled logistics solutions for the biopharma industry, has launched its innovative IntegriCell™ cryopreservation solution alongside the opening of a new facility at its Houston campus. This strategic move aims to enhance the efficiency and reliability of cell and gene therapy supply chains, supporting the growing demand for advanced therapies.

IntegriCell™, Cryoport's cutting-edge cryopreservation solution, improves the efficiency and reliability of cell and gene therapy supply chains by offering a seamless, end-to-end process for the storage, transportation, and distribution of critical materials. This innovative technology ensures the preservation of cell viability and potency, reducing the risk of contamination and enhancing the overall quality of therapies.

The new Houston facility, situated south of the city near the Texas Medical Center campus, spans approximately 21,000 sq ft and houses state-of-the-art equipment, systems, and processes. This GMP-compliant facility offers controlled temperature storage and fulfillment, secondary packaging and labeling, and kit production, all under one roof. The strategic location of the facility enables Cryoport to serve local, domestic, and international clients, streamlining supply chain processes and reducing lead times.

The new Houston facility's GMP-compliant storage and fulfillment capabilities enhance clients' advanced therapy programs by ensuring the highest quality and compliance in the handling and distribution of critical materials. Additionally, Cryoport's new secondary packaging and kit production services provide clients with a comprehensive range of services tailored to their clinical and commercial advanced therapy programs.

The proximity of the new Houston facility to the Texas Medical Center campus and its international accessibility benefit clients by facilitating the efficient transportation and distribution of therapies. This strategic location, combined with Cryoport's integrated logistics capabilities, enables clients to optimize their supply chain processes and accelerate the delivery of advanced therapies to patients worldwide.

Cryoport's expansion in Houston contributes to the growth of the life sciences research sector and the local economy by creating jobs, fostering innovation, and attracting investments in the region. The new Global Supply Chain Center will strengthen Cryoport's capabilities and service offerings, both regionally and nationwide, further solidifying its presence in the Houston market.

In conclusion, Cryoport's launch of IntegriCell™ and the opening of its new Houston facility represent a significant milestone in the evolution of cell and gene therapy supply chains. These innovative solutions and strategic investments will enhance the efficiency, reliability, and scalability of advanced therapy supply chains, ultimately accelerating the commercialization of new therapies and improving patient access to life-saving treatments.
Disclaimer: the above is a summary showing certain market information. AInvest is not responsible for any data errors, omissions or other information that may be displayed incorrectly as the data is derived from a third party source. Communications displaying market prices, data and other information available in this post are meant for informational purposes only and are not intended as an offer or solicitation for the purchase or sale of any security. Please do your own research when investing. All investments involve risk and the past performance of a security, or financial product does not guarantee future results or returns. Keep in mind that while diversification may help spread risk, it does not assure a profit, or protect against loss in a down market.